Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events

In This Article:

Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.